Concomitant Medication Effects on Patients with Lung Cancer Taking Immune Checkpoint Inhibitors a Review

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2025 Jan 6

PMID 39762456

Authors

Han Deng

Junxiang Zhou

Zhixi Liu

Lu Huang

Yanru Gu

Peng Chen

Hongtao Xiao

Affiliations

Soon will be listed here.

Abstract

In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment. In view of drug interactions, concomitant medications have a positive or negative impact on the prognosis of lung cancer patients. In this review, we reviewed the effects of multiple drugs on the prognosis of patients with lung cancer taking ICIs. Several studies indicate that antibiotics, proton pump inhibitors (PPIs), corticosteroids, and opioid analgesics can decrease the efficacy of ICIs. Aspirin and bone-targeting drugs can enhance the efficacy of ICIs and improve the survival rate. The effects of metformin (MET), renin-angiotensin-aldosterone system inhibitors (RASI), nonsteroidal anti-inflammatory drug (NSAIDS) (except aspirin), and statins on ICIs are controversial. Future research should further explore the effects of these concomitant medications on ICIs and develop personalized prescriptions based on the specific needs of patients.

References

Gun S, Lee S, Sieow J, Wong S . Targeting immune cells for cancer therapy. Redox Biol. 2019; 25:101174. PMC: 6859550. DOI: 10.1016/j.redox.2019.101174. View

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

Rezayi M, Hosseini A . Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct. 2023; 41(7):726-737. DOI: 10.1002/cbf.3827. View

Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

Shen D, Bi Y, Pang J, Zhao L, Zhao L, Gao Y . Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci. 2022; 79(8):413. PMC: 11073444. DOI: 10.1007/s00018-022-04431-x. View

Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q . Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Front Oncol. 2021; 11:771335. PMC: 8635629. DOI: 10.3389/fonc.2021.771335. View

Han Y, Liu D, Li L . PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3):727-742. PMC: 7136921. View

Brunet J, Denizot F, Luciani M, Suzan M, Mattei M, Golstein P . A new member of the immunoglobulin superfamily--CTLA-4. Nature. 1987; 328(6127):267-70. DOI: 10.1038/328267a0. View

Shiravand Y, Khodadadi F, Kashani S, Hosseini-Fard S, Hosseini S, Sadeghirad H . Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022; 29(5):3044-3060. PMC: 9139602. DOI: 10.3390/curroncol29050247. View

10.

Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker M . Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019; 142:26-34. DOI: 10.1016/j.critrevonc.2019.07.005. View

11.

Sieber B, Strauss J, Li Z, Gatti-Mays M . Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity. Front Oncol. 2022; 12:836934. PMC: 9196183. DOI: 10.3389/fonc.2022.836934. View

12.

Cook M, Wright G . The past, present, and future of antibiotics. Sci Transl Med. 2022; 14(657):eabo7793. DOI: 10.1126/scitranslmed.abo7793. View

13.

Araji G, Maamari J, Ali Ahmad F, Zareef R, Chaftari P, Yeung S . The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review. J Immunother Precis Oncol. 2022; 5(1):13-25. PMC: 9138420. DOI: 10.36401/JIPO-21-10. View

14.

Swami U, Zakharia Y, Zhang J . Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother. 2018; 41(8):359-360. DOI: 10.1097/CJI.0000000000000232. View

15.

Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F . Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist. 2019; 25(1):55-63. PMC: 6964118. DOI: 10.1634/theoncologist.2019-0160. View

16.

Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T . Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019; 130:10-17. DOI: 10.1016/j.lungcan.2019.01.017. View

17.

Pinato D, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T . Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. 2019; 5(12):1774-1778. PMC: 6743060. DOI: 10.1001/jamaoncol.2019.2785. View

18.

Ahmed J, Kumar A, Parikh K, Anwar A, Knoll B, Puccio C . Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018; 7(11):e1507670. PMC: 6205076. DOI: 10.1080/2162402X.2018.1507670. View

19.

Cortellini A, Ricciuti B, Facchinetti F, Alessi J, Venkatraman D, DallOlio F . Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021; 32(11):1391-1399. DOI: 10.1016/j.annonc.2021.08.1744. View

20.

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts J . Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021; 9(4). PMC: 8031700. DOI: 10.1136/jitc-2021-002421. View